Cohance Lifesciences Limited — Important, 01-01-2025: General Updates

Suven Pharmaceuticals has completed the merger of its wholly owned subsidiary, Casper Pharma Private Limited, into the main company, effective January 1, 2025. This consolidation comes after the necessary approvals from regulatory bodies, which included a recent sanction from the National Company Law Tribunal (NCLT). The merger is expected to streamline operations and enhance operational efficiencies, potentially leading to improved financial performance. With Casper Pharma now dissolved, Suven can focus on integrating its capabilities and resources. Investors should view this as a strategic move that could position the company for future growth opportunities while monitoring any impacts on operational alignment and market performance.